Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study

Clicks: 48
ID: 318955
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #15 of 54 articles by views in modern rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objectives To identify factors associated with flare after glucocorticoid (GC) reduction in systemic lupus erythematosus (SLE) and determine whether belimumab influences this risk. Methods Using the ANSWER-SLE cohort, this retrospective multicentre study enrolled 388 patients with GC reduction from ≤5 mg/day. The primary outcome was time to overall flare (SLE Disease Activity Index 2000 [SLEDAI-2K] increase ≥3 or GC escalation). Multivariable Cox models identified factors associated with overall flare. Propensity score-based matching weights were applied, and weighted Cox models assessed the association between belimumab and flare risk. Results During one-year follow-up, 133 overall flares occurred (1-year cumulative incidence 39.9%). Higher clinical SLEDAI (hazard ratio [HR] 1.10, 95% confidence interval [CI] 1.03–1.17), SDI (HR 1.11, 95% CI 1.01–1.22), and GC dose reduction (HR 1.40, 95% CI 1.15–1.70) were associated with increased overall flare risk. GC reductions >1 mg were associated with flare (HR 2.53, 95% CI 1.54–4.15). In weighted analyses, belimumab was not associated with overall flare (HR 0.83, 95% CI 0.51–1.34). Conclusions In patients with SLE, carefully tapering GC doses from ≤5 mg/day according to disease activity and organ damage may be important, whereas belimumab was not associated with reduced flare risk.
Reference Key
openalex_W7166152646 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hirofumi Miyake, Akira Ōnishi, Hideaki Tsuji, Takuya Kotani, Yumiko Wada, Yuji Nozaki, Toshihiko Shiga, S. Iwata, Takao Fujii, Yasuhiro Kato, Eri Itotagawa, Shuji Sumitomo, Hideki Oka, Wataru Yamamoto, Masao Katsushima, Motomu Hashimoto
Are you one of these authors? Claim your profile
Journal modern rheumatology
Year 2026
DOI
10.1093/mr/roag053
URL
https://doi.org/10.1093/mr/roag053
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.